Martin Kolb Selected Research

Inflammation (Inflammations)

1/2021	Role of the COX2-PGE2 axis in S. pneumoniae-induced exacerbation of experimental fibrosis.
1/2016	Human mesenchymal stem cells attenuate early damage in a ventilated pig model of acute lung injury.
7/2015	A novel profibrotic mechanism mediated by TGFβ-stimulated collagen prolyl hydroxylase expression in fibrotic lung mesenchymal cells.
1/2008	The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis?
6/2006	Targeting genes for treatment in idiopathic pulmonary fibrosis: challenges and opportunities, promises and pitfalls.
10/2005	TGF-beta and Smad3 signaling link inflammation to chronic fibrogenesis.
11/2004	Connective tissue growth factor is crucial to inducing a profibrotic environment in "fibrosis-resistant" BALB/c mouse lungs.
1/2003	Re-evaluation of fibrogenic cytokines in lung fibrosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Martin Kolb Research Topics

Disease

50	Idiopathic Pulmonary Fibrosis 12/2023 - 01/2008
45	Fibrosis (Cirrhosis) 10/2022 - 06/2002
30	Pulmonary Fibrosis (Fibrosing Alveolitis) 04/2024 - 08/2002
19	Interstitial Lung Diseases (Interstitial Lung Disease) 03/2024 - 05/2009
16	Disease Progression 03/2023 - 04/2009
10	Infections 01/2021 - 10/2001
8	Inflammation (Inflammations) 01/2021 - 01/2003
6	Rheumatoid Arthritis 02/2024 - 01/2019
5	Lung Diseases (Lung Disease) 10/2019 - 08/2010
4	Neoplasms (Cancer) 08/2022 - 10/2002
4	Pulmonary Hypertension 01/2022 - 05/2009
4	Emphysema 01/2019 - 11/2006
3	Cough 03/2024 - 01/2022
3	Dyspnea (Shortness of Breath) 02/2024 - 01/2016
3	Extrinsic Allergic Alveolitis (Hypersensitivity Pneumonitis) 12/2023 - 01/2019
3	Hypoxia (Hypoxemia) 12/2023 - 09/2017
2	Systemic Scleroderma (Systemic Sclerosis) 02/2024 - 01/2019
2	Idiopathic Interstitial Pneumonias 01/2022 - 01/2020
2	Pneumonia (Pneumonitis) 01/2022 - 10/2015
2	Liver Cirrhosis (Hepatic Cirrhosis) 01/2022 - 12/2012
2	Diarrhea 10/2019 - 05/2014
2	Cardiovascular Diseases (Cardiovascular Disease) 01/2019 - 01/2017
2	Hyperplasia 10/2016 - 09/2011
2	Vascular Remodeling 01/2013 - 05/2009
2	Peritoneal Fibrosis 03/2002 - 10/2001
1	Myositis (Idiopathic Inflammatory Myopathies) 02/2024
1	Pulmonary Atelectasis 01/2024
1	Chronic Cough 12/2023
1	Bronchiectasis 09/2023
1	Connective Tissue Diseases (Connective Tissue Disease) 10/2022
1	Mesothelioma 08/2022
1	Malignant Mesothelioma 08/2022
1	Asbestosis 08/2022
1	Pleural Diseases 08/2022

Drug/Important Bio-Agent (IBA)

27	nintedanibIBA 12/2023 - 05/2014
11	CollagenIBA 01/2022 - 10/2001
10	Biomarkers (Surrogate Marker)IBA 12/2023 - 04/2009
10	Bleomycin (Blenoxane)FDA LinkGeneric 01/2022 - 11/2004
9	Proteins (Proteins, Gene)FDA Link 07/2022 - 08/2002
8	CytokinesIBA 03/2022 - 10/2001
8	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2018 - 08/2002
8	Transforming Growth Factor beta (TGF-beta)IBA 01/2008 - 10/2001
7	pirfenidoneIBA 01/2023 - 01/2016
6	Transforming Growth Factor beta1 (TGF beta 1)IBA 05/2009 - 10/2001
5	Carbon MonoxideIBA 02/2024 - 10/2019
5	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2018 - 01/2003
4	Oxygen (Dioxygen)IBA 12/2023 - 01/2016
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 03/2022 - 06/2002
3	AnticoagulantsIBA 01/2021 - 01/2016
3	Anti-Bacterial Agents (Antibiotics)IBA 01/2020 - 11/2011
3	Phosphotransferases (Kinase)IBA 10/2019 - 04/2005
3	Hydroxyproline (4 Hydroxyproline)IBA 01/2018 - 10/2001
3	Proteoglycans (Proteoglycan)IBA 03/2014 - 03/2002
2	AntigensIBA 12/2023 - 01/2018
2	AsbestosIBA 08/2022 - 11/2007
2	Messenger RNA (mRNA)IBA 01/2022 - 12/2012
2	treprostinil FDA Link 01/2022 - 05/2021
2	Heat-Shock Proteins (Heat-Shock Protein)IBA 08/2021 - 01/2017
2	Sildenafil Citrate (Viagra)FDA Link 12/2019 - 11/2018
2	Tyrosine (L-Tyrosine)FDA Link 10/2019 - 01/2019
2	Therapeutic UsesIBA 01/2019 - 10/2016
2	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2018 - 01/2017
2	Protein-Lysine 6-Oxidase (Lysyl Oxidase)IBA 01/2018 - 01/2018
2	AntacidsIBA 01/2017 - 01/2016
2	Transcription Factors (Transcription Factor)IBA 01/2016 - 07/2012
2	IntegrinsIBA 01/2016 - 12/2014
2	Crystallins (Crystallin)IBA 02/2015 - 03/2014
2	ChondroitinIBA 03/2014 - 02/2011
2	GlycosaminoglycansIBA 03/2014 - 02/2011
2	EnzymesIBA 03/2014 - 02/2011
2	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 11/2011 - 01/2003
2	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 10/2011 - 05/2009
2	Tissue Inhibitor of Metalloproteinase-1IBA 11/2004 - 10/2003
2	Connective Tissue Growth FactorIBA 11/2004 - 10/2003
1	Carbon DioxideIBA 03/2024
1	beta-cyclodextrin tetradecasulfate (CTDS)IBA 02/2024
1	AcidsIBA 12/2023
1	Ion Channels (Ion Channel)IBA 12/2023
1	Oxyhemoglobins (Oxyhemoglobin)IBA 12/2023
1	cyclopropapyrroloindoleIBA 12/2023
1	Antirheumatic Agents (DMARD)IBA 12/2023
1	GlucocorticoidsIBA 09/2023
1	Type 4 Cyclic Nucleotide PhosphodiesterasesIBA 03/2023
1	Rheumatoid FactorIBA 10/2022
1	Peptides (Polypeptides)IBA 10/2022
1	MicroRNAs (MicroRNA)IBA 08/2022
1	MesothelinIBA 08/2022
1	Glycoproteins (Glycoprotein)IBA 08/2022
1	Matrix Metalloproteinases (MMPs)IBA 07/2022
1	ZincIBA 07/2022
1	GelatinasesIBA 07/2022

Therapy/Procedure

26	Therapeutics 03/2024 - 11/2007
4	Precision Medicine 04/2024 - 10/2015
3	Peritoneal Dialysis 02/2005 - 03/2002
2	Palliative Care (Palliative Therapy) 01/2023 - 12/2017
2	Lung Transplantation 01/2023 - 10/2022
1	Positive-Pressure Respiration (Positive End-Expiratory Pressure) 01/2024
1	Traction 09/2023
1	Treatment Delay 03/2023
1	Ambulatory Care (Outpatient Care) 01/2023